ARTV · Artiva Biotherapeutics, Inc.
$7.04
+0.21 (+3.07%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$344.19M
Shares
48.89M
Volume · Oct 5
323.57K
Avg daily vol (3M)
405.09K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.83
Open$6.89
Day$6.74–7.00
52W close$2.74–13.39
Avg vol 30d429K
Short int2.1M · 4.2% float · 6.7d
Short vol76%
Last earningsJun 8, 2026
DataJul 2024–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$90.82M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$349.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+61.7%
Year over year · more shares
Price change (1Y)
+131.5%
Trailing year
Short interest
4.2%
Latest settlement · 6.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−33%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
38%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−5%
trailing
YTD return
+59%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+80% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$4.0M over 90 days · 80% sells
Short interest
Rising
4.22% of float · ▲ +12.5% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 2-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+41%
Y/Y
Free cash flow
$-79.3M
Quant / Vol
risk profile
Volatility
182%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
38%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+80% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$4.0M over 90 days · 80% sells
Short interest
Rising
4.22% of float · ▲ +12.5% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $7 · 38%
Range high $13
vs 200-day avg -13%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARTV
this stock
Artiva Biotherapeutics, Inc.
|
$344.19M | +59.2% | -100.0% | — | 4.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARTV | -2.3% | -38.6% | -4.9% | -4.1% | +59.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -2.1% | -38.2% | -17.1% | -5.0% | +46.4% |